Jinluan Li1, Jianji Pan1, Xianggao Zhu2, Ying Su1, Lingling Bao1, Sufang Qiu1, Changyan Zou1, Yong Cai3, Junxin Wu1, Ivan W K Tham4. 1. Department of Radiation Oncology, Teaching Hospital of Fujian Medical University, Fujian Provincial Cancer Hospital, Fuzhou 350014, China; 2. Department of Radiation Oncology, Peking University People's Hospital, Beijing 100044, China; 3. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China; 4. Department of Radiation Oncology, National University Cancer Institute, Singapore 119228, Singapore.
Abstract
OBJECTIVE: In this study, we examine the effects of recombinant adenovirus-p53 (rAd-p53) on the pancreatic carcinoma cell line SW1990. Specifically, we determine if expression of rAd-p53 sensitizes these cells to radiation. METHODS: Following transfection of SW1990 cells with rAd-p53, we measured expression of P53, P21 and Bax by immunocytochemistry. Both transfected and control cell lines were irradiated with a range of doses, and the survival fractions (SF) were calculated. Dose survival curves were constructed and modeled for comparison. RESULTS: Transfection of SW1990 cells with rAd-p53 resulted in increased expression of P53, P21 and Bax in a time-dependent manner. At 96 h after transfection, 89.92% of cells expressed P53, 56.8% expressed P21, and 76.50% expressed Bax. The SF following radiation was lower in the rAd-p53 transfected cells compared to the control cells, suggesting that rAd-p53 sensitizes SW1990 cells to radiation (D0 for the experimental and control groups was 2.199 and 2.462, respectively). CONCLUSIONS: Use of the adenoviral vector is an effective means of transfecting SW1990 cells with wild-type P53, and this sensitizes the cell line to irradiation. This work suggests that combining rAd-p53 with radiation therapy in pancreatic cancer may be therapeutically beneficial.
OBJECTIVE: In this study, we examine the effects of recombinant adenovirus-p53 (rAd-p53) on the pancreatic carcinoma cell line SW1990. Specifically, we determine if expression of rAd-p53 sensitizes these cells to radiation. METHODS: Following transfection of SW1990 cells with rAd-p53, we measured expression of P53, P21 and Bax by immunocytochemistry. Both transfected and control cell lines were irradiated with a range of doses, and the survival fractions (SF) were calculated. Dose survival curves were constructed and modeled for comparison. RESULTS: Transfection of SW1990 cells with rAd-p53 resulted in increased expression of P53, P21 and Bax in a time-dependent manner. At 96 h after transfection, 89.92% of cells expressed P53, 56.8% expressed P21, and 76.50% expressed Bax. The SF following radiation was lower in the rAd-p53 transfected cells compared to the control cells, suggesting that rAd-p53 sensitizes SW1990 cells to radiation (D0 for the experimental and control groups was 2.199 and 2.462, respectively). CONCLUSIONS: Use of the adenoviral vector is an effective means of transfecting SW1990 cells with wild-type P53, and this sensitizes the cell line to irradiation. This work suggests that combining rAd-p53 with radiation therapy in pancreatic cancer may be therapeutically beneficial.
Authors: Meraj Mohiuddin; Damodaran Chendil; Swatee Dey; Rachael A Alcock; William Regine; Mohammed Mohiuddin; Mansoor M Ahmed Journal: Anticancer Res Date: 2002 Mar-Apr Impact factor: 2.480
Authors: J L Merlin; G Dolivet; C Dubessy; E Festor; R M Parache; L Verneuil; P Erbacher; J P Behr; F Guillemin Journal: Cancer Gene Ther Date: 2001-03 Impact factor: 5.987
Authors: E Mercadé; M Cascalló; M Carrió; J Calbó; A Gómez-Treviño; C Fillat; A M Gómez-Foix; A Mazo Journal: Ann Oncol Date: 2001-03 Impact factor: 32.976
Authors: James F Curtin; Marianela Candolfi; Weidong Xiong; Pedro R Lowenstein; Maria G Castro Journal: Mol Cancer Ther Date: 2008-03 Impact factor: 6.261